Specialty Pharma Journal Specialty, Precision & Technology
ENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced …
Read More »FDA Approves Merck’s Recarbrio for Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
Recent Posts
AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Collaborate to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill. & UTRECHT & ROTTERDAM, The Netherlands & SUZHOU, China–(BUSINESS …
Read More »Phase 3 Comparison Study of Novartis’ Enerzair Breezhaler Meets Primary Endpoint in Patients with Uncontrolled Asthma
Basel, June 5, 2020 — Novartis today announced that full results from the Phase IIIb ARGON …
Read More »Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis
FOSTER CITY, Calif. & MECHELEN, Belgium–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext …
Read More »FDA Grants Fast Track Designation to TVAC Biomedical’s Vaccine-Enhanced Adoptive T-Cell Therapy for Treatment of Glioblastoma Multiforme
OLATHE, Kan., June 4, 2020 /PRNewswire/ — TVAX Biomedical announced today receipt of Fast Track …
Read More »AstraZeneca and Accent Therapeutics Partner to Discover and Develop Novel Cancer Therapeutics
LEXINGTON, Mass.–(BUSINESS WIRE)–Accent Therapeutics and AstraZeneca (LSE/STO/NYSE: AZN) will collaborate to discover, develop and commercialize …
Read More »FDA Grants Emergency Use Authorization to Roche’s Elecsys IL-6 Test to Identify Patients at High Risk of Severe Inflammatory Response
Basel, 04 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the …
Read More »Sarclisa Combination Therapy Demonstrated Superior Progression Free Survival and Clinical Response in Patients with Relapsed Multiple Myeloma
PARIS – June 2, 2020 – Sarclisa® (isatuximab) added to carfilzomib and dexamethasone (Sarclisa combination therapy) reduced …
Read More »FDA Extends Review for Novartis’ sBLA for Ofatumumab in Patients with Relapsing Multiple Sclerosis
Basel, June 2, 2020 — Novartis today announced that it has received notice from the US …
Read More »Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement
BERKELEY, Calif., VANCOUVER, British Columbia and SEATTLE, Wash., June 02, 2020 (GLOBE NEWSWIRE) — Aduro …
Read More »CSL Behring and Seattle Children’s Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases
SEATTLE and KING of PRUSSIA, Pa., June 2, 2020 /PRNewswire/ — Seattle Children’s Research Institute, …
Read More »Bristol Myers Squibb Announces Positive Topline Results from Phase 3 True North Trial Evaluating Zeposia in Moderate to Severe Ulcerative Colitis
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE:BMY) today announced results from True North, a pivotal Phase 3 …
Read More »Personalis Announces Scientific Collaboration with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics
MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with Sarepta Therapeutics (Nasdaq: …
Read More »Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments for Hemophilia
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced an expansion of their existing collaboration to provide Regeneron with …
Read More »Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the Phase …
Read More »